Format

Send to

Choose Destination
J Dermatolog Treat. 2020 May;31(3):213-221. doi: 10.1080/09546634.2019.1592096. Epub 2019 May 1.

The real world impact of adalimumab on quality of life and the physical and psychological effects of moderate-to-severe psoriasis: a UK prospective, multicenter, observational study.

Author information

1
Department of Dermatology, Western Infirmary, Glasgow, United Kingdom.
2
Department of Dermatology, Castle Hill Hospital, East Yorkshire, United Kingdom.
3
Department of Dermatology, Harrogate and District NHS Foundation Trust, Harrogate, United Kingdom.
4
Department of Dermatology, Cannock Chase Hospital, Cannock, United Kingdom.
5
Department of Dermatology, The Royal Free Hospital, London, United Kingdom.
6
Department of Dermatology, East Surrey Hospital, Redhill, United Kingdom.
7
Department of Dermatology, Royal Devon & Exeter Hospital, Exeter, United Kingdom.
8
AbbVie Limited, Maidenhead, United Kingdom.
9
Department of Dermatology, Barts Health NHS Trust (Whipps Cross and Royal London Hospitals), London, United Kingdom.

Abstract

Psoriasis can adversely affect quality of life (QoL) and emotional well-being. In this UK prospective observational study we evaluated the 'real-world' impact of adalimumab on QoL and the physical/psychological effects of moderate-to-severe psoriasis. Hundred and forty-three biologic-naïve patients with moderate-to-severe psoriasis, receiving adalimumab in clinical practice, were included. Patients completed a series of questionnaires at baseline (adalimumab initiation), 4 and 16-weeks and 6-months post-adalimumab initiation during routine visits. The main outcome measure was the proportion of Dermatology Life Quality Index (DLQI) 'responders' at 16 weeks, defined as ≥5 point reduction from baseline or DLQI = 0.90% (95% CI = 80.8%-94.6%) of evaluable patients were DLQI responders at 16-weeks. There were significant improvements at 16 weeks in patient-reported measures of QoL, mental and physical well-being, cutaneous body image, anxiety, depression and psoriasis severity, which were maintained at 6-months. Adalimumab treatment was associated with improvements in patients' QoL and psychological functioning, which occurred contemporaneously with improvements in cutaneous disease.

KEYWORDS:

Adalimumab; body image; psoriasis; quality of life

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center